AU2002250869B2 - Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs - Google Patents

Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs Download PDF

Info

Publication number
AU2002250869B2
AU2002250869B2 AU2002250869A AU2002250869A AU2002250869B2 AU 2002250869 B2 AU2002250869 B2 AU 2002250869B2 AU 2002250869 A AU2002250869 A AU 2002250869A AU 2002250869 A AU2002250869 A AU 2002250869A AU 2002250869 B2 AU2002250869 B2 AU 2002250869B2
Authority
AU
Australia
Prior art keywords
prevention
treatment
transplanted
salt
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002250869A
Other languages
English (en)
Other versions
AU2002250869A1 (en
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of AU2002250869A1 publication Critical patent/AU2002250869A1/en
Application granted granted Critical
Publication of AU2002250869B2 publication Critical patent/AU2002250869B2/en
Assigned to DOMPE PHA.R.MA S.P.A. reassignment DOMPE PHA.R.MA S.P.A. Request for Assignment Assignors: DOMPE S.P.A.
Assigned to DOMPE' FARMACEUTICI S.P.A. reassignment DOMPE' FARMACEUTICI S.P.A. Request to Amend Deed and Register Assignors: DOMPE' PHA.R.MA S.P.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2002250869A 2001-02-02 2002-01-30 Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs Ceased AU2002250869B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2001A000206 2001-02-02
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (2)

Publication Number Publication Date
AU2002250869A1 AU2002250869A1 (en) 2003-02-13
AU2002250869B2 true AU2002250869B2 (en) 2006-10-19

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002250869A Ceased AU2002250869B2 (en) 2001-02-02 2002-01-30 Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Country Status (26)

Country Link
US (1) US7560487B2 (enExample)
EP (1) EP1355641B1 (enExample)
JP (1) JP2004517948A (enExample)
KR (1) KR100857898B1 (enExample)
CN (1) CN1561205A (enExample)
AT (1) ATE304846T1 (enExample)
AU (1) AU2002250869B2 (enExample)
BR (2) BRPI0206804B1 (enExample)
CA (1) CA2432432C (enExample)
CZ (1) CZ303665B6 (enExample)
DE (1) DE60206245T2 (enExample)
DK (1) DK1355641T3 (enExample)
EE (1) EE05233B1 (enExample)
ES (1) ES2248541T3 (enExample)
HU (1) HU229070B1 (enExample)
IL (1) IL157180A (enExample)
IT (1) ITMI20010206A1 (enExample)
MX (1) MXPA03006686A (enExample)
NO (1) NO334285B1 (enExample)
NZ (1) NZ526655A (enExample)
PL (1) PL215109B1 (enExample)
PT (1) PT1355641E (enExample)
RU (1) RU2257895C2 (enExample)
SK (1) SK287632B6 (enExample)
WO (1) WO2002062330A2 (enExample)
ZA (1) ZA200304861B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004003673T2 (de) * 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
HUE065802T2 (hu) * 2017-03-15 2024-06-28 Numares Ag Marker-készlet alkalmazása vesekilökõdés kockázatának meghatározására

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024710A1 (en) * 1998-10-23 2000-05-04 Dompe' S.P.A. N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
PL363576A1 (en) 2004-11-29
EE05233B1 (et) 2009-12-15
ZA200304861B (en) 2004-06-30
IL157180A (en) 2009-06-15
RU2003126600A (ru) 2005-02-27
MXPA03006686A (es) 2004-05-31
NO20033273D0 (no) 2003-07-18
ES2248541T3 (es) 2006-03-16
PT1355641E (pt) 2005-11-30
HU229070B1 (hu) 2013-07-29
SK9732003A3 (en) 2003-11-04
BRPI0206804B1 (pt) 2018-09-25
US7560487B2 (en) 2009-07-14
CA2432432A1 (en) 2002-08-15
HUP0303024A2 (hu) 2003-12-29
DE60206245T2 (de) 2006-06-14
NO20033273L (no) 2003-07-18
SK287632B6 (sk) 2011-04-05
NO334285B1 (no) 2014-01-27
WO2002062330A2 (en) 2002-08-15
EP1355641B1 (en) 2005-09-21
NZ526655A (en) 2005-02-25
RU2257895C2 (ru) 2005-08-10
EE200300340A (et) 2003-10-15
EP1355641A2 (en) 2003-10-29
WO2002062330A3 (en) 2003-04-03
CZ303665B6 (cs) 2013-02-20
DK1355641T3 (da) 2005-10-17
CN1561205A (zh) 2005-01-05
PL215109B1 (pl) 2013-10-31
CA2432432C (en) 2008-03-25
CZ20032095A3 (en) 2004-05-12
JP2004517948A (ja) 2004-06-17
KR100857898B1 (ko) 2008-09-10
BR0206804A (pt) 2004-02-03
ATE304846T1 (de) 2005-10-15
KR20030074725A (ko) 2003-09-19
US20040102520A1 (en) 2004-05-27
ITMI20010206A1 (it) 2002-08-02
HUP0303024A3 (en) 2005-07-28
DE60206245D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
COHEN et al. Small intestinal transplantation using cyclosporine: report of a case
Andoh et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
JP2644955B2 (ja) 過剰増殖血管病の治療用医薬組成物
CA2432432C (en) Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
Faure et al. Polyethylene glycol reduces early and long-term cold ischemia-reperfusion and renal medulla injury
Gabbiani et al. Morphologic and functional changes of the aortic intima during experimental hypertension
AU2002250869A1 (en) Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
US20080234236A1 (en) Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
Jeremy et al. Cigarette smoke extracts, but not nicotine, inhibit prostacyclin (PGI2) synthesis in human, rabbit and rat vascular tissue
EP0910355B1 (en) Traitement and prevention of adverse effects of reactive oxygen species
US20030139368A1 (en) Antithrombotic and/or anti-inflammatory composition combining purine activity and NSAID activity
Eknoyan Analgesic nephrotoxicity and renal papillary necrosis
JP3771446B2 (ja) 新規な免疫抑制剤
Frick et al. Secondary ischaemia in experimental free flaps–treatment by long acting prostacyclin analogues
Hjelms et al. Accelerated cholesterol accumulation in homologous arterial transplants in cholesterol-fed rabbits. A surgical model to study transplantation atherosclerosis.
CA2660260A1 (en) Use of modified interleukin-8 proteins
HK1071853A (en) Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
JPH0680582A (ja) 脂質代謝改善剤
JP2796647B2 (ja) マグノロール及び／またはホウノキオールを有効成分とする血管攣縮抑制剤
Brambilla et al. TOXICITY OF N-DIAZOACETYLGLYCINE HYDRAZIDE (NSC-58404) IN ANIMALS 1, 2
KR100616020B1 (ko) 맥관장애및이종이식술에서의라파마이신유도체의용도
Marino et al. Antibody binding to endothelial and epithelial antigens triggers pig‐to‐rabbit xenograft rejection and its absence results in atypical complement deposition
Perico et al. Altered Renovascular Endothelial Functions During Nephrotoxicity
JPS6224406B2 (enExample)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DOMPE PHA.R.MA S.P.A.

Free format text: FORMER APPLICANT(S): DOMPE S.P.A.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired